Table of Content

1 Study Coverage
1.1 Hyperuricemia Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Hyperuricemia Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 NSAIDs
1.2.3 Xanthine Oxidase Inhibitor
1.2.4 Selective Uric Acid Reabsorption Inhibitor
1.2.5 Carbonic Anhydrase Inhibitor
1.2.6 Glucocorticoid
1.2.7 Other
1.3 Market by Application
1.3.1 Global Hyperuricemia Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Gout
1.3.3 Renal Calculus
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Hyperuricemia Drugs Sales Estimates and Forecasts 2018-2029
2.2 Global Hyperuricemia Drugs Revenue by Region
2.2.1 Global Hyperuricemia Drugs Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Hyperuricemia Drugs Revenue by Region (2018-2024)
2.2.3 Global Hyperuricemia Drugs Revenue by Region (2024-2029)
2.2.4 Global Hyperuricemia Drugs Revenue Market Share by Region (2018-2029)
2.3 Global Hyperuricemia Drugs Sales Estimates and Forecasts 2018-2029
2.4 Global Hyperuricemia Drugs Sales by Region
2.4.1 Global Hyperuricemia Drugs Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Hyperuricemia Drugs Sales by Region (2018-2024)
2.4.3 Global Hyperuricemia Drugs Sales by Region (2024-2029)
2.4.4 Global Hyperuricemia Drugs Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Hyperuricemia Drugs Sales by Manufacturers
3.1.1 Global Hyperuricemia Drugs Sales by Manufacturers (2018-2024)
3.1.2 Global Hyperuricemia Drugs Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Hyperuricemia Drugs in 2022
3.2 Global Hyperuricemia Drugs Revenue by Manufacturers
3.2.1 Global Hyperuricemia Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Hyperuricemia Drugs Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Hyperuricemia Drugs Revenue in 2022
3.3 Global Key Players of Hyperuricemia Drugs, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Hyperuricemia Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Hyperuricemia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Hyperuricemia Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Hyperuricemia Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Hyperuricemia Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Hyperuricemia Drugs Sales by Type
4.1.1 Global Hyperuricemia Drugs Historical Sales by Type (2018-2024)
4.1.2 Global Hyperuricemia Drugs Forecasted Sales by Type (2024-2029)
4.1.3 Global Hyperuricemia Drugs Sales Market Share by Type (2018-2029)
4.2 Global Hyperuricemia Drugs Revenue by Type
4.2.1 Global Hyperuricemia Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Hyperuricemia Drugs Forecasted Revenue by Type (2024-2029)
4.2.3 Global Hyperuricemia Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Hyperuricemia Drugs Price by Type
4.3.1 Global Hyperuricemia Drugs Price by Type (2018-2024)
4.3.2 Global Hyperuricemia Drugs Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Hyperuricemia Drugs Sales by Application
5.1.1 Global Hyperuricemia Drugs Historical Sales by Application (2018-2024)
5.1.2 Global Hyperuricemia Drugs Forecasted Sales by Application (2024-2029)
5.1.3 Global Hyperuricemia Drugs Sales Market Share by Application (2018-2029)
5.2 Global Hyperuricemia Drugs Revenue by Application
5.2.1 Global Hyperuricemia Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Hyperuricemia Drugs Forecasted Revenue by Application (2024-2029)
5.2.3 Global Hyperuricemia Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Hyperuricemia Drugs Price by Application
5.3.1 Global Hyperuricemia Drugs Price by Application (2018-2024)
5.3.2 Global Hyperuricemia Drugs Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Hyperuricemia Drugs Market Size by Type
6.1.1 US & Canada Hyperuricemia Drugs Sales by Type (2018-2029)
6.1.2 US & Canada Hyperuricemia Drugs Revenue by Type (2018-2029)
6.2 US & Canada Hyperuricemia Drugs Market Size by Application
6.2.1 US & Canada Hyperuricemia Drugs Sales by Application (2018-2029)
6.2.2 US & Canada Hyperuricemia Drugs Revenue by Application (2018-2029)
6.3 US & Canada Hyperuricemia Drugs Market Size by Country
6.3.1 US & Canada Hyperuricemia Drugs Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Hyperuricemia Drugs Sales by Country (2018-2029)
6.3.3 US & Canada Hyperuricemia Drugs Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Hyperuricemia Drugs Market Size by Type
7.1.1 Europe Hyperuricemia Drugs Sales by Type (2018-2029)
7.1.2 Europe Hyperuricemia Drugs Revenue by Type (2018-2029)
7.2 Europe Hyperuricemia Drugs Market Size by Application
7.2.1 Europe Hyperuricemia Drugs Sales by Application (2018-2029)
7.2.2 Europe Hyperuricemia Drugs Revenue by Application (2018-2029)
7.3 Europe Hyperuricemia Drugs Market Size by Country
7.3.1 Europe Hyperuricemia Drugs Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Hyperuricemia Drugs Sales by Country (2018-2029)
7.3.3 Europe Hyperuricemia Drugs Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Hyperuricemia Drugs Market Size
8.1.1 China Hyperuricemia Drugs Sales (2018-2029)
8.1.2 China Hyperuricemia Drugs Revenue (2018-2029)
8.2 China Hyperuricemia Drugs Market Size by Application
8.2.1 China Hyperuricemia Drugs Sales by Application (2018-2029)
8.2.2 China Hyperuricemia Drugs Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Hyperuricemia Drugs Market Size by Type
9.1.1 Asia Hyperuricemia Drugs Sales by Type (2018-2029)
9.1.2 Asia Hyperuricemia Drugs Revenue by Type (2018-2029)
9.2 Asia Hyperuricemia Drugs Market Size by Application
9.2.1 Asia Hyperuricemia Drugs Sales by Application (2018-2029)
9.2.2 Asia Hyperuricemia Drugs Revenue by Application (2018-2029)
9.3 Asia Hyperuricemia Drugs Sales by Region
9.3.1 Asia Hyperuricemia Drugs Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Hyperuricemia Drugs Revenue by Region (2018-2029)
9.3.3 Asia Hyperuricemia Drugs Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Hyperuricemia Drugs Market Size by Type
10.1.1 Middle East, Africa and Latin America Hyperuricemia Drugs Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Hyperuricemia Drugs Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Hyperuricemia Drugs Market Size by Application
10.2.1 Middle East, Africa and Latin America Hyperuricemia Drugs Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Hyperuricemia Drugs Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Hyperuricemia Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America Hyperuricemia Drugs Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Hyperuricemia Drugs Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Hyperuricemia Drugs Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Horizon Therapeutics plc
11.1.1 Horizon Therapeutics plc Company Information
11.1.2 Horizon Therapeutics plc Overview
11.1.3 Horizon Therapeutics plc Hyperuricemia Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Horizon Therapeutics plc Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Horizon Therapeutics plc Recent Developments
11.2 Takeda Pharmaceutical Company Ltd
11.2.1 Takeda Pharmaceutical Company Ltd Company Information
11.2.2 Takeda Pharmaceutical Company Ltd Overview
11.2.3 Takeda Pharmaceutical Company Ltd Hyperuricemia Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Takeda Pharmaceutical Company Ltd Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Takeda Pharmaceutical Company Ltd Recent Developments
11.3 Mylan NV
11.3.1 Mylan NV Company Information
11.3.2 Mylan NV Overview
11.3.3 Mylan NV Hyperuricemia Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Mylan NV Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Mylan NV Recent Developments
11.4 Novartis International AG
11.4.1 Novartis International AG Company Information
11.4.2 Novartis International AG Overview
11.4.3 Novartis International AG Hyperuricemia Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Novartis International AG Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novartis International AG Recent Developments
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Company Information
11.5.2 Regeneron Pharmaceuticals Overview
11.5.3 Regeneron Pharmaceuticals Hyperuricemia Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Regeneron Pharmaceuticals Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Regeneron Pharmaceuticals Recent Developments
11.6 Romeg Therapeutics
11.6.1 Romeg Therapeutics Company Information
11.6.2 Romeg Therapeutics Overview
11.6.3 Romeg Therapeutics Hyperuricemia Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Romeg Therapeutics Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Romeg Therapeutics Recent Developments
11.7 Teijin Pharma Ltd
11.7.1 Teijin Pharma Ltd Company Information
11.7.2 Teijin Pharma Ltd Overview
11.7.3 Teijin Pharma Ltd Hyperuricemia Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Teijin Pharma Ltd Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Teijin Pharma Ltd Recent Developments
11.8 Lannett Company, Inc
11.8.1 Lannett Company, Inc Company Information
11.8.2 Lannett Company, Inc Overview
11.8.3 Lannett Company, Inc Hyperuricemia Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Lannett Company, Inc Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Lannett Company, Inc Recent Developments
11.9 GSK Plc
11.9.1 GSK Plc Company Information
11.9.2 GSK Plc Overview
11.9.3 GSK Plc Hyperuricemia Drugs Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 GSK Plc Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 GSK Plc Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Hyperuricemia Drugs Industry Chain Analysis
12.2 Hyperuricemia Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hyperuricemia Drugs Production Mode & Process
12.4 Hyperuricemia Drugs Sales and Marketing
12.4.1 Hyperuricemia Drugs Sales Channels
12.4.2 Hyperuricemia Drugs Distributors
12.5 Hyperuricemia Drugs Customers
13 Market Dynamics
13.1 Hyperuricemia Drugs Industry Trends
13.2 Hyperuricemia Drugs Market Drivers
13.3 Hyperuricemia Drugs Market Challenges
13.4 Hyperuricemia Drugs Market Restraints
14 Key Findings in The Global Hyperuricemia Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Hyperuricemia Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of NSAIDs
Table 3. Major Manufacturers of Xanthine Oxidase Inhibitor
Table 4. Major Manufacturers of Selective Uric Acid Reabsorption Inhibitor
Table 5. Major Manufacturers of Carbonic Anhydrase Inhibitor
Table 6. Major Manufacturers of Glucocorticoid
Table 7. Major Manufacturers of Other
Table 8. Global Hyperuricemia Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 9. Global Hyperuricemia Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 10. Global Hyperuricemia Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 11. Global Hyperuricemia Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 12. Global Hyperuricemia Drugs Revenue Market Share by Region (2018-2024)
Table 13. Global Hyperuricemia Drugs Revenue Market Share by Region (2024-2029)
Table 14. Global Hyperuricemia Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 15. Global Hyperuricemia Drugs Sales by Region (2018-2024) & (K Units)
Table 16. Global Hyperuricemia Drugs Sales by Region (2024-2029) & (K Units)
Table 17. Global Hyperuricemia Drugs Sales Market Share by Region (2018-2024)
Table 18. Global Hyperuricemia Drugs Sales Market Share by Region (2024-2029)
Table 19. Global Hyperuricemia Drugs Sales by Manufacturers (2018-2024) & (K Units)
Table 20. Global Hyperuricemia Drugs Sales Share by Manufacturers (2018-2024)
Table 21. Global Hyperuricemia Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 22. Global Hyperuricemia Drugs Revenue Share by Manufacturers (2018-2024)
Table 23. Global Key Players of Hyperuricemia Drugs, Industry Ranking, 2021 VS 2022 VS 2024
Table 24. Hyperuricemia Drugs Price by Manufacturers 2018-2024 (US$/Unit)
Table 25. Global Hyperuricemia Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Hyperuricemia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperuricemia Drugs as of 2022)
Table 27. Global Key Manufacturers of Hyperuricemia Drugs, Manufacturing Base Distribution and Headquarters
Table 28. Global Key Manufacturers of Hyperuricemia Drugs, Product Offered and Application
Table 29. Global Key Manufacturers of Hyperuricemia Drugs, Date of Enter into This Industry
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Hyperuricemia Drugs Sales by Type (2018-2024) & (K Units)
Table 32. Global Hyperuricemia Drugs Sales by Type (2024-2029) & (K Units)
Table 33. Global Hyperuricemia Drugs Sales Share by Type (2018-2024)
Table 34. Global Hyperuricemia Drugs Sales Share by Type (2024-2029)
Table 35. Global Hyperuricemia Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 36. Global Hyperuricemia Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 37. Global Hyperuricemia Drugs Revenue Share by Type (2018-2024)
Table 38. Global Hyperuricemia Drugs Revenue Share by Type (2024-2029)
Table 39. Hyperuricemia Drugs Price by Type (2018-2024) & (US$/Unit)
Table 40. Global Hyperuricemia Drugs Price Forecast by Type (2024-2029) & (US$/Unit)
Table 41. Global Hyperuricemia Drugs Sales by Application (2018-2024) & (K Units)
Table 42. Global Hyperuricemia Drugs Sales by Application (2024-2029) & (K Units)
Table 43. Global Hyperuricemia Drugs Sales Share by Application (2018-2024)
Table 44. Global Hyperuricemia Drugs Sales Share by Application (2024-2029)
Table 45. Global Hyperuricemia Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 46. Global Hyperuricemia Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 47. Global Hyperuricemia Drugs Revenue Share by Application (2018-2024)
Table 48. Global Hyperuricemia Drugs Revenue Share by Application (2024-2029)
Table 49. Hyperuricemia Drugs Price by Application (2018-2024) & (US$/Unit)
Table 50. Global Hyperuricemia Drugs Price Forecast by Application (2024-2029) & (US$/Unit)
Table 51. US & Canada Hyperuricemia Drugs Sales by Type (2018-2024) & (K Units)
Table 52. US & Canada Hyperuricemia Drugs Sales by Type (2024-2029) & (K Units)
Table 53. US & Canada Hyperuricemia Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 54. US & Canada Hyperuricemia Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 55. US & Canada Hyperuricemia Drugs Sales by Application (2018-2024) & (K Units)
Table 56. US & Canada Hyperuricemia Drugs Sales by Application (2024-2029) & (K Units)
Table 57. US & Canada Hyperuricemia Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 58. US & Canada Hyperuricemia Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 59. US & Canada Hyperuricemia Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 60. US & Canada Hyperuricemia Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 61. US & Canada Hyperuricemia Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 62. US & Canada Hyperuricemia Drugs Sales by Country (2018-2024) & (K Units)
Table 63. US & Canada Hyperuricemia Drugs Sales by Country (2024-2029) & (K Units)
Table 64. Europe Hyperuricemia Drugs Sales by Type (2018-2024) & (K Units)
Table 65. Europe Hyperuricemia Drugs Sales by Type (2024-2029) & (K Units)
Table 66. Europe Hyperuricemia Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Hyperuricemia Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 68. Europe Hyperuricemia Drugs Sales by Application (2018-2024) & (K Units)
Table 69. Europe Hyperuricemia Drugs Sales by Application (2024-2029) & (K Units)
Table 70. Europe Hyperuricemia Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Hyperuricemia Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 72. Europe Hyperuricemia Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 73. Europe Hyperuricemia Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Hyperuricemia Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 75. Europe Hyperuricemia Drugs Sales by Country (2018-2024) & (K Units)
Table 76. Europe Hyperuricemia Drugs Sales by Country (2024-2029) & (K Units)
Table 77. China Hyperuricemia Drugs Sales by Type (2018-2024) & (K Units)
Table 78. China Hyperuricemia Drugs Sales by Type (2024-2029) & (K Units)
Table 79. China Hyperuricemia Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 80. China Hyperuricemia Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 81. China Hyperuricemia Drugs Sales by Application (2018-2024) & (K Units)
Table 82. China Hyperuricemia Drugs Sales by Application (2024-2029) & (K Units)
Table 83. China Hyperuricemia Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 84. China Hyperuricemia Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 85. Asia Hyperuricemia Drugs Sales by Type (2018-2024) & (K Units)
Table 86. Asia Hyperuricemia Drugs Sales by Type (2024-2029) & (K Units)
Table 87. Asia Hyperuricemia Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 88. Asia Hyperuricemia Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 89. Asia Hyperuricemia Drugs Sales by Application (2018-2024) & (K Units)
Table 90. Asia Hyperuricemia Drugs Sales by Application (2024-2029) & (K Units)
Table 91. Asia Hyperuricemia Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 92. Asia Hyperuricemia Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 93. Asia Hyperuricemia Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 94. Asia Hyperuricemia Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 95. Asia Hyperuricemia Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 96. Asia Hyperuricemia Drugs Sales by Region (2018-2024) & (K Units)
Table 97. Asia Hyperuricemia Drugs Sales by Region (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Hyperuricemia Drugs Sales by Type (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Hyperuricemia Drugs Sales by Type (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Hyperuricemia Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Hyperuricemia Drugs Revenue by Type (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Hyperuricemia Drugs Sales by Application (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Hyperuricemia Drugs Sales by Application (2024-2029) & (K Units)
Table 104. Middle East, Africa and Latin America Hyperuricemia Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Hyperuricemia Drugs Revenue by Application (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Hyperuricemia Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 107. Middle East, Africa and Latin America Hyperuricemia Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Hyperuricemia Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 109. Middle East, Africa and Latin America Hyperuricemia Drugs Sales by Country (2018-2024) & (K Units)
Table 110. Middle East, Africa and Latin America Hyperuricemia Drugs Sales by Country (2024-2029) & (K Units)
Table 111. Horizon Therapeutics plc Company Information
Table 112. Horizon Therapeutics plc Description and Major Businesses
Table 113. Horizon Therapeutics plc Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 114. Horizon Therapeutics plc Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Horizon Therapeutics plc Recent Developments
Table 116. Takeda Pharmaceutical Company Ltd Company Information
Table 117. Takeda Pharmaceutical Company Ltd Description and Major Businesses
Table 118. Takeda Pharmaceutical Company Ltd Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 119. Takeda Pharmaceutical Company Ltd Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Takeda Pharmaceutical Company Ltd Recent Developments
Table 121. Mylan NV Company Information
Table 122. Mylan NV Description and Major Businesses
Table 123. Mylan NV Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 124. Mylan NV Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Mylan NV Recent Developments
Table 126. Novartis International AG Company Information
Table 127. Novartis International AG Description and Major Businesses
Table 128. Novartis International AG Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 129. Novartis International AG Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Novartis International AG Recent Developments
Table 131. Regeneron Pharmaceuticals Company Information
Table 132. Regeneron Pharmaceuticals Description and Major Businesses
Table 133. Regeneron Pharmaceuticals Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 134. Regeneron Pharmaceuticals Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Regeneron Pharmaceuticals Recent Developments
Table 136. Romeg Therapeutics Company Information
Table 137. Romeg Therapeutics Description and Major Businesses
Table 138. Romeg Therapeutics Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 139. Romeg Therapeutics Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Romeg Therapeutics Recent Developments
Table 141. Teijin Pharma Ltd Company Information
Table 142. Teijin Pharma Ltd Description and Major Businesses
Table 143. Teijin Pharma Ltd Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 144. Teijin Pharma Ltd Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Teijin Pharma Ltd Recent Developments
Table 146. Lannett Company, Inc Company Information
Table 147. Lannett Company, Inc Description and Major Businesses
Table 148. Lannett Company, Inc Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 149. Lannett Company, Inc Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Lannett Company, Inc Recent Developments
Table 151. GSK Plc Company Information
Table 152. GSK Plc Description and Major Businesses
Table 153. GSK Plc Hyperuricemia Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 154. GSK Plc Hyperuricemia Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. GSK Plc Recent Developments
Table 156. Key Raw Materials Lists
Table 157. Raw Materials Key Suppliers Lists
Table 158. Hyperuricemia Drugs Distributors List
Table 159. Hyperuricemia Drugs Customers List
Table 160. Hyperuricemia Drugs Market Trends
Table 161. Hyperuricemia Drugs Market Drivers
Table 162. Hyperuricemia Drugs Market Challenges
Table 163. Hyperuricemia Drugs Market Restraints
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of Figures
Figure 1. Hyperuricemia Drugs Product Picture
Figure 2. Global Hyperuricemia Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Hyperuricemia Drugs Market Share by Type in 2022 & 2029
Figure 4. NSAIDs Product Picture
Figure 5. Xanthine Oxidase Inhibitor Product Picture
Figure 6. Selective Uric Acid Reabsorption Inhibitor Product Picture
Figure 7. Carbonic Anhydrase Inhibitor Product Picture
Figure 8. Glucocorticoid Product Picture
Figure 9. Other Product Picture
Figure 10. Global Hyperuricemia Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 11. Global Hyperuricemia Drugs Market Share by Application in 2022 & 2029
Figure 12. Gout
Figure 13. Renal Calculus
Figure 14. Other
Figure 15. Hyperuricemia Drugs Report Years Considered
Figure 16. Global Hyperuricemia Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Hyperuricemia Drugs Revenue 2018-2029 (US$ Million)
Figure 18. Global Hyperuricemia Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 19. Global Hyperuricemia Drugs Revenue Market Share by Region (2018-2029)
Figure 20. Global Hyperuricemia Drugs Sales 2018-2029 ((K Units)
Figure 21. Global Hyperuricemia Drugs Sales Market Share by Region (2018-2029)
Figure 22. US & Canada Hyperuricemia Drugs Sales YoY (2018-2029) & (K Units)
Figure 23. US & Canada Hyperuricemia Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 24. Europe Hyperuricemia Drugs Sales YoY (2018-2029) & (K Units)
Figure 25. Europe Hyperuricemia Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 26. China Hyperuricemia Drugs Sales YoY (2018-2029) & (K Units)
Figure 27. China Hyperuricemia Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Asia (excluding China) Hyperuricemia Drugs Sales YoY (2018-2029) & (K Units)
Figure 29. Asia (excluding China) Hyperuricemia Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Hyperuricemia Drugs Sales YoY (2018-2029) & (K Units)
Figure 31. Middle East, Africa and Latin America Hyperuricemia Drugs Revenue YoY (2018-2029) & (US$ Million)
Figure 32. The Hyperuricemia Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 33. The Top 5 and 10 Largest Manufacturers of Hyperuricemia Drugs in the World: Market Share by Hyperuricemia Drugs Revenue in 2022
Figure 34. Global Hyperuricemia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 35. Global Hyperuricemia Drugs Sales Market Share by Type (2018-2029)
Figure 36. Global Hyperuricemia Drugs Revenue Market Share by Type (2018-2029)
Figure 37. Global Hyperuricemia Drugs Sales Market Share by Application (2018-2029)
Figure 38. Global Hyperuricemia Drugs Revenue Market Share by Application (2018-2029)
Figure 39. US & Canada Hyperuricemia Drugs Sales Market Share by Type (2018-2029)
Figure 40. US & Canada Hyperuricemia Drugs Revenue Market Share by Type (2018-2029)
Figure 41. US & Canada Hyperuricemia Drugs Sales Market Share by Application (2018-2029)
Figure 42. US & Canada Hyperuricemia Drugs Revenue Market Share by Application (2018-2029)
Figure 43. US & Canada Hyperuricemia Drugs Revenue Share by Country (2018-2029)
Figure 44. US & Canada Hyperuricemia Drugs Sales Share by Country (2018-2029)
Figure 45. U.S. Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 46. Canada Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 47. Europe Hyperuricemia Drugs Sales Market Share by Type (2018-2029)
Figure 48. Europe Hyperuricemia Drugs Revenue Market Share by Type (2018-2029)
Figure 49. Europe Hyperuricemia Drugs Sales Market Share by Application (2018-2029)
Figure 50. Europe Hyperuricemia Drugs Revenue Market Share by Application (2018-2029)
Figure 51. Europe Hyperuricemia Drugs Revenue Share by Country (2018-2029)
Figure 52. Europe Hyperuricemia Drugs Sales Share by Country (2018-2029)
Figure 53. Germany Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 54. France Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 55. U.K. Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 56. Italy Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 57. Russia Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 58. China Hyperuricemia Drugs Sales Market Share by Type (2018-2029)
Figure 59. China Hyperuricemia Drugs Revenue Market Share by Type (2018-2029)
Figure 60. China Hyperuricemia Drugs Sales Market Share by Application (2018-2029)
Figure 61. China Hyperuricemia Drugs Revenue Market Share by Application (2018-2029)
Figure 62. Asia Hyperuricemia Drugs Sales Market Share by Type (2018-2029)
Figure 63. Asia Hyperuricemia Drugs Revenue Market Share by Type (2018-2029)
Figure 64. Asia Hyperuricemia Drugs Sales Market Share by Application (2018-2029)
Figure 65. Asia Hyperuricemia Drugs Revenue Market Share by Application (2018-2029)
Figure 66. Asia Hyperuricemia Drugs Revenue Share by Region (2018-2029)
Figure 67. Asia Hyperuricemia Drugs Sales Share by Region (2018-2029)
Figure 68. Japan Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 69. South Korea Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 70. China Taiwan Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 71. Southeast Asia Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 72. India Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 73. Middle East, Africa and Latin America Hyperuricemia Drugs Sales Market Share by Type (2018-2029)
Figure 74. Middle East, Africa and Latin America Hyperuricemia Drugs Revenue Market Share by Type (2018-2029)
Figure 75. Middle East, Africa and Latin America Hyperuricemia Drugs Sales Market Share by Application (2018-2029)
Figure 76. Middle East, Africa and Latin America Hyperuricemia Drugs Revenue Market Share by Application (2018-2029)
Figure 77. Middle East, Africa and Latin America Hyperuricemia Drugs Revenue Share by Country (2018-2029)
Figure 78. Middle East, Africa and Latin America Hyperuricemia Drugs Sales Share by Country (2018-2029)
Figure 79. Brazil Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 80. Mexico Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 81. Turkey Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 82. Israel Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 83. GCC Countries Hyperuricemia Drugs Revenue (2018-2029) & (US$ Million)
Figure 84. Hyperuricemia Drugs Value Chain
Figure 85. Hyperuricemia Drugs Production Process
Figure 86. Channels of Distribution
Figure 87. Distributors Profiles
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed